 Yuwen Zhu
Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 7 | 2021 | 1774 | 1.690 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 200 | 1.440 |
Why?
| | Neoplasms | 7 | 2022 | 2179 | 1.310 |
Why?
| | Tumor Microenvironment | 4 | 2022 | 454 | 1.090 |
Why?
| | Immunotherapy | 5 | 2022 | 493 | 1.060 |
Why?
| | Receptors, Cell Surface | 2 | 2017 | 367 | 0.990 |
Why?
| | Lymphocyte Activation | 6 | 2016 | 1067 | 0.960 |
Why?
| | Immunity | 2 | 2021 | 129 | 0.930 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 118 | 0.930 |
Why?
| | CD28 Antigens | 3 | 2013 | 46 | 0.890 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 3 | 2013 | 18 | 0.870 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 16 | 0.840 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 22 | 0.840 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 40 | 0.830 |
Why?
| | Melanoma | 2 | 2022 | 664 | 0.820 |
Why?
| | Signal Transduction | 9 | 2022 | 4709 | 0.790 |
Why?
| | Pancreatic Neoplasms | 2 | 2020 | 734 | 0.750 |
Why?
| | Immunomodulation | 2 | 2018 | 89 | 0.730 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 167 | 0.690 |
Why?
| | Killer Cells, Natural | 2 | 2023 | 381 | 0.680 |
Why?
| | Thalidomide | 1 | 2018 | 28 | 0.660 |
Why?
| | Immunologic Factors | 2 | 2018 | 225 | 0.660 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 356 | 0.600 |
Why?
| | Trastuzumab | 1 | 2017 | 92 | 0.590 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 144 | 0.590 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2016 | 5 | 0.570 |
Why?
| | Receptors, Immunologic | 1 | 2017 | 209 | 0.560 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2016 | 35 | 0.560 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2016 | 20 | 0.550 |
Why?
| | Immunoglobulins | 2 | 2023 | 154 | 0.550 |
Why?
| | Ligands | 7 | 2023 | 567 | 0.550 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 156 | 0.520 |
Why?
| | Cell Adhesion Molecules | 1 | 2016 | 180 | 0.510 |
Why?
| | Skin Neoplasms | 1 | 2022 | 762 | 0.490 |
Why?
| | Central Nervous System | 1 | 2016 | 245 | 0.480 |
Why?
| | Animals | 18 | 2022 | 33381 | 0.440 |
Why?
| | Pancreas | 1 | 2014 | 282 | 0.430 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2014 | 210 | 0.420 |
Why?
| | Mice | 11 | 2022 | 15520 | 0.410 |
Why?
| | Cell Line, Tumor | 4 | 2021 | 2851 | 0.400 |
Why?
| | Models, Immunological | 1 | 2011 | 94 | 0.390 |
Why?
| | HEK293 Cells | 3 | 2021 | 625 | 0.380 |
Why?
| | Antibodies, Monoclonal | 4 | 2016 | 1284 | 0.360 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2022 | 1167 | 0.340 |
Why?
| | Ovarian Neoplasms | 1 | 2013 | 420 | 0.330 |
Why?
| | Biomarkers, Tumor | 1 | 2014 | 1059 | 0.320 |
Why?
| | Mice, Knockout | 4 | 2022 | 2680 | 0.320 |
Why?
| | Adenocarcinoma | 1 | 2014 | 812 | 0.320 |
Why?
| | Cell Movement | 2 | 2022 | 896 | 0.310 |
Why?
| | Antineoplastic Agents | 1 | 2018 | 1974 | 0.300 |
Why?
| | Cell Membrane | 1 | 2011 | 710 | 0.300 |
Why?
| | Membrane Proteins | 1 | 2013 | 1055 | 0.290 |
Why?
| | Immunologic Memory | 2 | 2010 | 313 | 0.270 |
Why?
| | Breast Neoplasms | 1 | 2017 | 1965 | 0.260 |
Why?
| | Inflammation | 1 | 2016 | 2566 | 0.260 |
Why?
| | Humans | 18 | 2023 | 118974 | 0.250 |
Why?
| | Protein Binding | 2 | 2022 | 1975 | 0.210 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2023 | 702 | 0.210 |
Why?
| | Recombinant Fusion Proteins | 2 | 2016 | 653 | 0.200 |
Why?
| | Neuropeptides | 1 | 2021 | 68 | 0.200 |
Why?
| | Chemokines | 1 | 2022 | 230 | 0.200 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2022 | 158 | 0.200 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2022 | 112 | 0.200 |
Why?
| | Carcinogenesis | 1 | 2022 | 182 | 0.200 |
Why?
| | Tumor Burden | 1 | 2022 | 274 | 0.190 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1206 | 0.180 |
Why?
| | Amino Acid Sequence | 2 | 2016 | 2071 | 0.180 |
Why?
| | Survival Analysis | 2 | 2022 | 1267 | 0.180 |
Why?
| | Dendritic Cells | 2 | 2016 | 442 | 0.180 |
Why?
| | Molecular Sequence Data | 2 | 2016 | 2871 | 0.170 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2016 | 632 | 0.170 |
Why?
| | Mice, Inbred C57BL | 4 | 2021 | 4908 | 0.160 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 2016 | 83 | 0.160 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2018 | 204 | 0.160 |
Why?
| | MCF-7 Cells | 1 | 2017 | 111 | 0.150 |
Why?
| | Nectins | 1 | 2016 | 4 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 1 | 2018 | 396 | 0.140 |
Why?
| | Endothelial Cells | 1 | 2021 | 732 | 0.140 |
Why?
| | Receptors, Virus | 1 | 2016 | 78 | 0.140 |
Why?
| | Cell Proliferation | 2 | 2021 | 2275 | 0.130 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 87 | 0.130 |
Why?
| | Blood-Brain Barrier | 1 | 2016 | 108 | 0.130 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2016 | 372 | 0.130 |
Why?
| | Immunoenzyme Techniques | 1 | 2014 | 195 | 0.120 |
Why?
| | Phosphotyrosine | 1 | 2013 | 37 | 0.110 |
Why?
| | Succinimides | 1 | 2013 | 17 | 0.110 |
Why?
| | Vanadates | 1 | 2013 | 29 | 0.110 |
Why?
| | B7 Antigens | 1 | 2013 | 11 | 0.110 |
Why?
| | Models, Molecular | 2 | 2016 | 1435 | 0.110 |
Why?
| | Fluoresceins | 1 | 2013 | 47 | 0.110 |
Why?
| | Tumor Cells, Cultured | 1 | 2014 | 874 | 0.110 |
Why?
| | Antigens, Surface | 1 | 2013 | 156 | 0.110 |
Why?
| | Lipopolysaccharides | 1 | 2016 | 870 | 0.110 |
Why?
| | Coculture Techniques | 1 | 2013 | 208 | 0.110 |
Why?
| | Phylogeny | 1 | 2016 | 816 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1597 | 0.100 |
Why?
| | Flow Cytometry | 1 | 2014 | 1085 | 0.100 |
Why?
| | Neoplasm Staging | 1 | 2014 | 1223 | 0.100 |
Why?
| | Epitopes | 1 | 2013 | 443 | 0.100 |
Why?
| | Genome, Human | 1 | 2013 | 387 | 0.090 |
Why?
| | B7-2 Antigen | 1 | 2009 | 25 | 0.090 |
Why?
| | Lymphocytes | 1 | 2011 | 347 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 2009 | 79 | 0.090 |
Why?
| | Immune Tolerance | 1 | 2011 | 334 | 0.080 |
Why?
| | B7-1 Antigen | 1 | 2009 | 69 | 0.080 |
Why?
| | Listeriosis | 1 | 2009 | 60 | 0.080 |
Why?
| | Antigens, CD | 1 | 2011 | 460 | 0.080 |
Why?
| | Phosphorylation | 1 | 2013 | 1633 | 0.080 |
Why?
| | History, 21st Century | 1 | 2009 | 170 | 0.080 |
Why?
| | Neurons | 1 | 2016 | 1345 | 0.080 |
Why?
| | History, 20th Century | 1 | 2009 | 281 | 0.080 |
Why?
| | Interleukin-15 | 1 | 2007 | 77 | 0.070 |
Why?
| | Prognosis | 1 | 2014 | 3443 | 0.070 |
Why?
| | Major Histocompatibility Complex | 1 | 2007 | 220 | 0.070 |
Why?
| | Mice, Transgenic | 2 | 2010 | 2025 | 0.070 |
Why?
| | Cell Division | 1 | 2007 | 776 | 0.060 |
Why?
| | Interferon-gamma | 1 | 2007 | 736 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2009 | 745 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2445 | 0.060 |
Why?
| | Receptors, KIR | 1 | 2023 | 89 | 0.060 |
Why?
| | Thymus Gland | 1 | 2023 | 300 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 310 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2007 | 984 | 0.050 |
Why?
| | Drug Delivery Systems | 1 | 2003 | 306 | 0.050 |
Why?
| | Female | 3 | 2017 | 61565 | 0.050 |
Why?
| | Cell Line | 2 | 2011 | 2707 | 0.030 |
Why?
| | Inducible T-Cell Co-Stimulator Ligand | 1 | 2011 | 1 | 0.030 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 1 | 2011 | 9 | 0.030 |
Why?
| | Protein Structure, Quaternary | 1 | 2011 | 116 | 0.020 |
Why?
| | CTLA-4 Antigen | 1 | 2011 | 86 | 0.020 |
Why?
| | Mice, Inbred DBA | 1 | 2010 | 174 | 0.020 |
Why?
| | Cancer Vaccines | 1 | 2010 | 139 | 0.020 |
Why?
| | Interleukin-12 | 1 | 2009 | 110 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2010 | 227 | 0.020 |
Why?
| | Toll-Like Receptors | 1 | 2009 | 167 | 0.020 |
Why?
| | Listeria monocytogenes | 1 | 2009 | 110 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1224 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 544 | 0.020 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2009 | 197 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2010 | 359 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2010 | 359 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 872 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1171 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2010 | 4077 | 0.010 |
Why?
|
|
Zhu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|